## **RESEARCH ARTICLE**



# Malignant mesothelioma following repeated exposures to cosmetic talc: A case series of 75 patients

Theresa S. Emory MD<sup>1</sup> [] John C. Maddox MD<sup>1</sup> [] Richard L. Kradin MD<sup>2,3</sup> []

<sup>1</sup>Department of Pathology, Peninsula Pathology Associates, Newport News, Virginia

<sup>2</sup>Department of Medicine (Pulmonary/Critical Care), Massachusetts General Hospital, Boston, Massachusetts

<sup>3</sup>Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts

#### Correspondence

Theresa S. Emory, MD, Department of Pathology, Peninsula Pathology Associates, 500 J Clyde Morris Blvd, Newport News, VA 23601.

Email: temorymd@gmail.com

### Abstract

**Background:** Asbestos is the primary known cause of malignant mesothelioma. Some cosmetic talc products have been shown to contain asbestos. Recently, repeated exposures to cosmetic talc have been implicated as a cause of mesothelioma.

**Methods:** Seventy-five individuals (64 females; 11 males) with malignant mesothelioma, whose only known exposure to asbestos was repeated exposures to cosmetic talcum powders, were reviewed in medical-legal consultation. Out of the 75 cases, 11 were examined for asbestiform fibers.

**Results:** All subjects had pathologically confirmed malignant mesothelioma. The mean age at diagnosis was  $61 \pm 17$  years. The mean latency from exposure to diagnosis was  $50 \pm 13$  years. The mean exposure duration was  $33 \pm 16$  years. Four mesotheliomas (5%) occurred in individuals working as barbers/cosmetologists, or in a family member who swept the barber shop. Twelve (16%) occurred in individuals less than 45 years old (10 females; 2 males). Forty-eight mesotheliomas were pleural (40 females; 8 males), 23 were peritoneal (21 females; 2 males). Two presented with concomitant pleural and peritoneal disease. There was one pericardial, and one testicular mesothelioma. The majority (51) were of the epithelioid histological subtype, followed by 13 biphasic, 8 sarcomatoid, 2 lymphohistiocytoid, and 1 poorly differentiated. Of the 11 individuals whose nontumorous tissues were analyzed for the presence of asbestiform fibers, all showed the presence of anthophyllite and/or tremolite asbestos.

**Conclusions:** Mesotheliomas can develop following exposures to cosmetic talcum powders. These appear to be attributable to the presence of anthophyllite and tremolite contaminants in cosmetic talcum powder.

#### KEYWORDS

anthophyllite, females, mesothelioma, peritoneal, pleural, talc, tremolite

# 1 | INTRODUCTION

Asbestos, a generic term for naturally occurring fibrous mineral silicates, is recognized as a carcinogen by the general medical and scientific communities. In 1960, Wagner et al<sup>1</sup> reported a large series

of malignant mesotheliomas in individuals who had been exposed to asbestos from a South African asbestos mine. It has been demonstrated that all types of asbestos and even brief and low-dose exposures are capable of causing malignant mesothelioma.<sup>2-4</sup> In the 1970s, several types of cosmetic talcum powder products were

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. American Journal of Industrial Medicine published by Wiley Periodicals, Inc.

demonstrated to contain asbestos.<sup>5-7</sup> Asbestos fibers in commercial talcum powder have also been shown to become airborne upon application, and repeated exposures to cosmetic talc were implicated as a cause of mesothelioma by Gordon et al.<sup>8</sup> Recently, Moline et al,<sup>9</sup> reported a series of 33 subjects with malignant mesothelioma, whose only known exposure to asbestos was cosmetic talc. We present 75 additional subjects, with malignant mesothelioma, whose only known exposure to asbestos was cosmetic talc.

# 2 | METHODS

One hundred forty subjects with documented exposures to cosmetic talc were initially reviewed. Exposures were identified through sworn deposition testimonies and answers to sworn interrogatories provided from subjects, parents, and spouses. Sixty-five subjects were excluded due to recalled occupational or paraoccupational exposures to other sources of asbestos. Seventy-five subjects, whose only known exposure to asbestos was via cosmetic talc, were included for further examination. The asbestos content of talcum products and airborne asbestos concentrations during simulations of the usage of these products was determined in previously published studies.<sup>10,11</sup>

Tissues from biopsies and/or debulking procedures were examined and the diagnosis of malignant mesothelioma was confirmed by a boardcertified pathologist (JCM, TSE, RLK). Immunohistochemical staining results for BAP-1 were available in a few cases but was not routinely performed as a part of this study.

No efforts were made to reconstruct levels of exposure but all subjects had been repeatedly exposed over many years. Eleven cases were examined for the presence of asbestiform fibers (aspect ratio,  $\ge$ 3:1) in sampled tissues. Nine subjects were examined both by analytical transmission electron microscopy (ATEM) and microprobe analysis (MA) (see Table 2), whereas two were examined by scanning electron microscopy (SEM) and MA (results not shown).

# 3 | RESULTS

The pertinent data from the 75 subjects is shown in Table 1. All had pathologically confirmed malignant mesothelioma. Sixty-four subjects were females, 11 were males. The mean age at diagnosis was  $61 \pm 17$  years, with a range of 14 to 94 years. The mean exposure duration was  $33 \pm 16$  years with a range of exposure from 6 to 65 years. The mean latency from time of first exposure to diagnosis was  $50 \pm 13$  years with a range of 14 to 72 years. A total of 4 of the 75 cases (5%) occurred in barbers/cosmetologists, or in a family member who swept the barber shop. Twelve (16%) were 45 years old or younger (10 females, 2 males) at the time of diagnosis. Forty-eight mesotheliomas were pleural (40 females; 8 in males); 23 peritoneal (21 females; 2 men). Two presented with both pleural and peritoneal disease. There was one pericardial (woman), and one testicular mesothelioma. The majority, 51 (68%) were of epithelioid subtype, 13 biphasic (17%), 8 sarcomatoid (11%), 2 lymphohistiocytoid (3%),

and 1 poorly differentiated (1%). Treatment, therapeutic outcomes, and survival were not determined in this study.

For the 11 subjects whose tissues were examined by ATEM and ASEM, the analysis showed the presence of tremolite and/or anthophyllite in all 11 subjects (Table 2).

# 4 | DISCUSSION

The 75 individuals with malignant mesothelioma caused by asbestos in cosmetic talc is currently the largest series reported to date. Recently, Moline et al reported 33 cases of malignant mesothelioma attributed to exposures to cosmetic talc. Like Moline's work, most of mesotheliomas in the present series occurred in women. Several mesotheliomas occurred specifically in hairdressers/barbers. Similarly, the asbestos fiber types found by ATEM in the tissues examined were comparable to those found in laboratory testing for cosmetic talc.<sup>10-12</sup>

Mesothelioma is recognized as a "signal tumor" of asbestos exposure, that is, if a patient has mesothelioma, it should signal an inquiry into potential asbestos exposure. The presence of asbestos in talc deposits has been recognized since the late 1940s.<sup>13,14</sup> Since the 1960s, laboratory testing has identified asbestos in samples of cosmetic talc.<sup>15,16</sup> Studies have confirmed that the most common types of asbestos present in cosmetic talc are tremolite, anthophyllite, and chrysotile. Industrial asbestos products used in the United States generally contained chrysotile, amosite, and/or crocidolite,<sup>17</sup> and anthophyllite and tremolite were rarely present.<sup>18</sup>

While the latency between exposure and diagnosis in the present study is similar to the average latency for the development of mesothelioma (50 years) reported in surveillance epidemiology and end results program (SEER) data,<sup>19</sup> the average age at diagnosis in this report (61 years) is 11 years younger than that in the SEER data (72 years). In addition, fewer than 3% of mesotheliomas in the SEER data occurred in individuals less than 45 years of age, whereas 16% of mesotheliomas of the present study occurred in individuals less than 45 years of age, and 83% of these cases were in women.<sup>20</sup>

The present report of 75 cases, together with the 35 cases previously reported<sup>8,9</sup> currently brings the number of individuals with confirmed diagnoses of malignant mesothelioma following repeated exposure to cosmetic talcum powder to more than 100. The presence of anthophyllite and tremolite in the fiber analysis of tissues obtained from the 11 subjects in this series, is consistent with a source in cosmetic talc.

Unlike industrial or occupational exposure to asbestos, where materials have been regulated, exposure to asbestos in cosmetic talc has not been widely reported or recognized within the medical community or to the public. Cosmetic talc products are most frequently used by women in the United States, and while the incidence of mesothelioma in women is less than in men, the majority have previously been reported as "idiopathic," indicating no recognized source of asbestos exposure. The present study supports the contention that asbestos exposure through the use of cosmetic talc accounts may account for an uncertain percentage of these cases. ---WILEY-

TABLE 1	Seventy-five	mesothelioma	cases exposed	to talcum powder
---------	--------------	--------------	---------------	------------------

no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no.no	Case	Sex	Year of diagnosis	Age at diagnosis	Mesothelioma site	Histology	Estimated years of use	Estimated years of latency
1         2014         51         Pertoneal         Epithelioid         30         50           3         F         2017         50         Pieural         Lymphohistocytold         41         50           4         F         2017         57         Pietroneal         Epithelioid         30         52           5         F         2015         57         Pietroneal         Saccomatoid         15         30           7         F         2014         39         Periconcial         Saccomatoid         30         32           7         F         2013         64         Pieural         Epithelioid         60         72           8         F         2013         64         Pieural         Epithelioid         30         52           10         F         2013         64         Pieural         Epithelioid         30         52           11         F         2013         64         Pieural         Epithelioid         30         52           12         F         2013         64         Pieural         Epithelioid         30         30           13         F         2013         52         Pieural <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td>•</td> <td></td>			-				•	
1         Pirat         Solor         Pirat         Piratorial         Lymphohistocycial         A1         Sol           4         F         2017         S7         Periconcal         Epitheliod         30         52           5         F         2017         37         Periconcal         Epitheliod         30         52           6         F         2017         39         Periconcal         Epitheliod         29         29           8         F         2013         80         Pericard         Epitheliod         29         21           9         F         2013         80         Pericard         Epitheliod         10         20         21           10         F         2013         51         Pericard         Epitheliod         13         21           11         F         2013         51         Pericard         Epitheliod         14         20           12         F         2013         51         Pericard         Epitheliod         13         21           13         F         2014         51         Pericard         Epitheliod         14         20           14         F         2013 </td <td>2</td> <td>F</td> <td>2014</td> <td>51</td> <td>Peritoneal</td> <td>Epithelioid</td> <td></td> <td>50</td>	2	F	2014	51	Peritoneal	Epithelioid		50
5F201565PieuralEpithelioid396267201739PeritoncalSarcomatoid1339777201629PericardialEpithelioid292987201594PieuralEpithelioid607297201572PieuralEpithelioid1359107201672PieuralSarcomatoid3151118201364PieuralEpithelioid1321128201364PieuralEpithelioid1321138201484PieuralEpithelioid1321148201851PietronalEpithelioid132115201951PietronalEpithelioid4852168201784PieuralSarcomatoid4852178201781PietronalEpithelioid4042189201782PieuralSarcomatoid4052198201784PieuralPietronalEpithelioid4052198201784PieuralPietronalEpithelioid305310820178PieuralPietronalEpithelioid3063119201470PieuralEpit			2017	50	Pleural	Lymphohistiocytoid	41	
AF201739PeritonealSarcomatoid19397F201629PericardialEpithelioid29298F201794PleuralEpithelioid60729F201580PleuralEpithelioid195910F201672PleuralSarcomatoid435911F201360PeritonealEpithelioid132113F201351PeritonealEpithelioid132014F201855PeritonealEpithelioid404215M201781PleuralSarcomatoid606016F201781PleuralSarcomatoid404217F201781PleuralSarcomatoid404218F201781PleuralSarcomatoid40431981201781PleuralSarcomatoid40431081201781PleuralSarcomatoid40431981201781PleuralSarcomatoid40431081201781PleuralSarcomatoid404311F201870PleuralSarcomatoid405310M201773PleuralEpithelioid1043 <t< td=""><td>4</td><td>F</td><td>2017</td><td>57</td><td>Peritoneal</td><td>Epithelioid</td><td>30</td><td>52</td></t<>	4	F	2017	57	Peritoneal	Epithelioid	30	52
7F201429PericardialEpithelioid29298F201794PleuralEpithelioid60729F201580PleuralEpithelioid195910F201672PleuralScromatoid435911F201364PeritonealEpithelioid105212F201148PeritonealEpithelioid102013F201251PeritonealEpithelioid404214F201351PeritonealEpithelioid404215M201781PeritonealEpithelioid404216F201856PeritonealEpithelioid404217F201856PeritonealEpithelioid404216V201781PeritonealEpithelioid404217F201782PeritonealEpithelioid505217F201782PeritonealEpithelioid505220M201673PeritonealEpithelioid505321F201664PeritonealEpithelioid506321F201674PeritonealEpithelioid50642223F201664PeritonealEpithelioid<	5	F	2015	65	Pleural	Epithelioid	39	62
8F201794PleuralEpitheliold60729F201580PleuralEpitheliold195910F201672PleuralSarcomatoid435911F201366PeritonealEpitheliold205212F201148PleuralEpitheliold132113F201351PleuralEpitheliold132114F201351PleuralEpitheliold432214F201354PleuralSarcomatoid432215M201781PleuralEpitheliold432216F201782PleuralSarcomatoid433217F201782PleuralSarcomatoid433218F201782PleuralSarcomatoid433219F201773PleuralSarcomatoid43321081201773PleuralSarcomatoid43321081201973PleuralSarcomatoid433310201973PleuralSarcomatoid4334341181201773PleuralSarcomatoid50535312F201874PleuralPleuralSarcomatoid5154	6	F	2017	39	Peritoneal	Sarcomatoid	15	39
9F201580PleuralEpithelioid199110F201472PleuralSarcomatoid435911F201364PeritonealEpithelioid205212F201448PleuralEpithelioid132113F201051PeritonealEpithelioid152014F201351PeritonealEpithelioid162014F201454PeritonealSarcomatoid606014F201781PleuralSarcomatoid402216F201781PleuralSarcomatoid402217F201782PleuralSarcomatoid405618F201782PleuralSarcomatoid40561973PleuralPleuralEpithelioid47561074PleuralPleuralEpithelioid405621F201673PleuralEpithelioid104522F201863PleuralEpithelioid106223F201873PleuralEpithelioid106224F201874PleuralEpithelioid106324F201874PleuralEpithelioid121224F	7	F	2016	29	Pericardial	Epithelioid	29	29
IndF201672PleuralSarcomatoid439911F201364PeritonealEpithelioid205212F201148PleuralLymphohisticcytoid132113F201051PeritonealEpithelioid152014F201855PeritonealEpithelioid404215M201781PleuralSarcomatoid606016F201856PleuralEpithelioid485217F201784PleuralSarcomatoid404218F201787PleuralSarcomatoid406219F201787PleuralPeritonealEpithelioid405320R201973PleuralPoritonealEpithelioid404321F201864PleuralEpithelioid104522F201864PleuralEpithelioid106423F201867PleuralEpithelioid136024F201867PleuralEpithelioid145925F201867PleuralEpithelioid155926F201867PleuralEpithelioid16505327F201867Pleural <td< td=""><td>8</td><td>F</td><td>2017</td><td>94</td><td>Pleural</td><td>Epithelioid</td><td>60</td><td>72</td></td<>	8	F	2017	94	Pleural	Epithelioid	60	72
11F201364PertonealEpithelioid205212F201051PertonealEpithelioid152013F201051PertonealEpithelioid404214F201855PertonealEpithelioid404215M201781PleuralSarcomatoid606016F201856PleuralEpithelioid435217F201732PertonealEpithelioid404218F201732PertonealEpithelioid404219F201732PertonealEpithelioid404220F201973PertonealEpithelioid404321F201664PleuralSorcomatoid404322F201845PleuralEpithelioid104523F201664PleuralEpithelioid104524M201778PertonealEpithelioid136025M201778PertonealEpithelioid145924F201867PleuralEpithelioid155725F201473PertonealEpithelioid16505726F201874PleuralEpithelioid165	9	F	2015	80	Pleural	Epithelioid	19	59
12F201148PleuralLymphohisticytoid132113F201051PeritonealEpithelioid152014F201855PeritonealEpithelioid404215M201781PleuralSarcomatoid606016F201856PleuralEpithelioid485217F201732PeritonealEpithelioid404218F201732PeritonealEpithelioid404219F201773PeritonealEpithelioid4043201M201670PleuralPoorly differentiated505521F201866PleuralEpithelioid104522F201864PleuralEpithelioid104523F201867PleuralEpithelioid104524M201567PleuralEpithelioid104525M201778PleuralEpithelioid104524M201778PleuralEpithelioid104525M201857F2018575726F201857PleuralEpithelioid155727F201873PleuralEpithelioid1557 <tr< td=""><td>10</td><td>F</td><td>2016</td><td>72</td><td>Pleural</td><td>Sarcomatoid</td><td>43</td><td>59</td></tr<>	10	F	2016	72	Pleural	Sarcomatoid	43	59
11F201051PeritonealEpithelioid1520114F201355PeritonealEpithelioid404215M201781PleuralSarcomatoid606016F201356PleuralEpithelioid485217F201732PeritonealEpithelioid404218F201789PleuralSarcomatoid404219F201973PeritonealEpithelioid475620M201670PleuralPoorly differentiated505521F201566PleuralEpithelioid104522F201845PleuralEpithelioid104523F201867PleuralEpithelioid104524M201564PleuralEpithelioid104525F201867PleuralEpithelioid104524M201778PeritonealEpithelioid124625F201867PleuralEpithelioid155726F201876PleuralEpithelioid165727F201876PleuralEpithelioid155729F201876PleuralEpithelioid1657<	11	F	2013	66	Peritoneal	Epithelioid	20	52
14F201855PeritonealEpithelioid404215M201781PleuralSarcomatoid606016F201856PleuralEpithelioid253217F201732PeritonealEpithelioid253218F201789PleuralSarcomatoid404219F201973PeritonealEpithelioid505520M201670PleuralPoorly differentiated505521F201566PleuralEpithelioid404322F201845PleuralEpithelioid104523F201845PleuralEpithelioid304524M201778PeritonealEpithelioid314025M201778PeritonealEpithelioid124126F201857PeritonealEpithelioid125727F201314PeritonealEpithelioid155729F201870PleuralEpithelioid165721M201739Feitheliod515733F201857PleuralEpithelioid165734F201857Feitheliod505735F	12	F	2011	48	Pleural	Lymphohistiocytoid	13	21
N201781PleuralSarcomatoid606016F201856PleuralEpithelioid485217F201732PeritonealEpithelioid213218F201789PleuralSarcomatoid404219F201973PeritonealEpithelioid475620M201670PleuralPoorly differentiated505221F201566PleuralEpithelioid104522F201645PleuralEpithelioid324523F201845Pleural peritonealEpithelioid104524M201778PeirtonealEpithelioid326025M201778PeritonealEpithelioid124526F201857PeritonealEpithelioid121427F201873PeritonealEpithelioid135928F201873PeritonealEpithelioid14505729F201873PeritonealEpithelioid145057201F201873PeritonealEpithelioid1557201F201873PeritonealEpithelioid737201F201874Peritoneal <t< td=""><td>13</td><td>F</td><td>2010</td><td>51</td><td>Peritoneal</td><td>Epithelioid</td><td>15</td><td>20</td></t<>	13	F	2010	51	Peritoneal	Epithelioid	15	20
16F201856PleuralEpithelioid485217F201732PeritonealEpithelioid253218F201789PleuralSacomatoid404219F201973PeritonealEpithelioid475620M20470PleuralPorly differentiated505521F201566PleuralEpithelioid404322F201645PleuralEpithelioid394523F201845PeritonealEpithelioid394524M201778PeritonealEpithelioid306225M201857PeritonealEpithelioid121426V201857PeritonealEpithelioid121427F201873PeritonealEpithelioid135927F201857PeritonealEpithelioid145928F201873PeritonealEpithelioid155929F201873PeritonealEpithelioid1659201F201873PeritonealEpithelioid1659201F201874PeritonealEpithelioid5057201F201874PeritonealEpithelioid	14	F	2018	55	Peritoneal	Epithelioid	40	42
17F201732PertonealEpithelioid253218F201789PeuralSarconatoid404219F201973PertonealEpithelioid475620M201670PeuralPoorly differentiated575721F201566PeuralEpithelioid104322F201645PeuralEpithelioid374523F201845PeuralEpithelioid366024M201767PeuralBiphasic576025M201778PertonealBiphasic505726F201857PertonealBiphasic121427F201314PertonealEpithelioid135927F201457PertonealBiphasic165927F201873PertonealEpithelioid155928F201873PertonealEpithelioid165929F201874PertonealEpithelioid165030F201454PertonealEpithelioid505731M201557PertonealEpithelioid505731F201454PertonealEpithelioid5057 <t< td=""><td>15</td><td>М</td><td>2017</td><td>81</td><td>Pleural</td><td>Sarcomatoid</td><td>60</td><td>60</td></t<>	15	М	2017	81	Pleural	Sarcomatoid	60	60
18F201789PleuralSarconatoid404219F201973PeritonealEpithelioid475620M201470PleuralPoorly differentiated505521F201566PleuralEpithelioid404322F201645PleuralEpithelioid104523F201845PleuralEpithelioid374524M201567Pleural+peritonealEpithelioid356025M201778PeritonealBiphasic506226F201857PeritonealBiphasic121427F201314PeritonealEpithelioid121428F201473PleuralEpithelioid125729F201873PleuralEpithelioid165520F201876PleuralEpithelioid165530F201476PleuralEpithelioid165731M201739PleuralEpithelioid703732F201458PleuralEpithelioid505733F201458PleuralEpithelioid505434F201458PleuralEpithelioid5054	16	F	2018	56	Pleural	Epithelioid	48	52
19F201973PeritonealEpithelioid475620M201670PleuralPoorly differentiated505521F201566PleuralEpithelioid404322F201645PleuralEpithelioid104523F201845PeritonealEpithelioid394524M201567Pleural + peritonealEpithelioid506225M201778PeritonealBiphasic506226F201857PeritonealBiphasic576227F201314PeritonealBiphasic121428F201857PeritonealEpithelioid121429F201873PeritonealEpithelioid121420F201873PeritonealEpithelioid121429F201873PeritonealEpithelioid1559204F201873PleuralBiphasic6055305F201874PleuralScoromation7439314M201781PleuralEpithelioid3661315F201663PleuralEpithelioid5060316F201663PleuralEpithelioid15	17	F	2017	32	Peritoneal	Epithelioid	25	32
20M201670PleuralPoorly differentiated505521F201566PleuralEpithelioid404322F201645PleuralEpithelioid104523F201845PeritonealEpithelioid394524M201567Pleural + peritonealEpithelioid356025M201778PeritonealBiphasic506226F201857PeritonealBiphasic121427F201314PeritonealEpithelioid155727F201667PeritonealEpithelioid155927F201873PeritonealEpithelioid165928F201873PeuralBiphasic605529F201873PeuralBiphasic165929F201873PeuralEpithelioid1559201F201874PeuralStoreal505530F201874PeuralEpithelioid505731M201780PeuralEpithelioid506033F201463PeuralEpithelioid506034F201463PeuralEpithelioid5154 <trr< td=""><td>18</td><td>F</td><td>2017</td><td>89</td><td>Pleural</td><td>Sarcomatoid</td><td>40</td><td>42</td></trr<>	18	F	2017	89	Pleural	Sarcomatoid	40	42
1F201566PleuralEpithelioid404322F201645PleuralEpithelioid104523F201845PeritonealEpithelioid394524M201567Pleural + peritonealEpithelioid356025M201778PeritonealBiphasic506226F201857PeritonealBiphasic255727F201314PeritonealEpithelioid121428F201667PeritonealEpithelioid155929F201873PeritonealEpithelioid155920F201876PleuralSrcomato605530F201876PleuralSinchaid575731M201739PleuralSinchaid575732F201857PleuralSinchaid575733F201668PleuralSinchaid506034F201780PleuralEpithelioid156435F201663PleuralEpithelioid156436F201758PleuralEpithelioid155437F201663PleuralEpithelioid605436 <td>19</td> <td>F</td> <td>2019</td> <td>73</td> <td>Peritoneal</td> <td>Epithelioid</td> <td>47</td> <td>56</td>	19	F	2019	73	Peritoneal	Epithelioid	47	56
22F201645PleuralEpithelioid104523F201845Epithelioid394524M201567Pleural + peritonealEpithelioid356025M201778PeritonealBiphasic506226F201857PeritonealBiphasic255727F201314PeritonealEpithelioid121428F201667PeritonealEpithelioid155929F201873PleuralEpithelioid306530F201876PleuralBiphasic605531M201739PleuralSarcomatoid575733F201857PleuralSarcomatoid575734F201780PleuralEpithelioid386435F201663PleuralEpithelioid506034F201780PleuralEpithelioid50605435F201663PleuralEpithelioid50636436F201758PleuralEpithelioid505436F201758PleuralEpithelioid505436F201758PleuralEpithelioid6071	20	М	2016	70	Pleural	Poorly differentiated	50	55
23F201845PeritonealEpithelioid394524M201567Pleural + peritonealEpithelioid356025M201778PeritonealBiphasic506226F201857PeritonealBiphasic255727F201314PeritonealEpithelioid121428F201667PeritonealEpithelioid155929F201873PleuralBiphasic306530F201876PleuralBiphasic605531M201739TestisBiphasic73932F201857PleuralSarcomatoid575733F201668PleuralSarcomatoid506034F201780PleuralBiphasic306435F201663PleuralEpithelioid316436F201780PleuralBiphasic205836F201758PleuralBiphasic605137F201758PleuralBiphasic605436F201758PleuralBiphasic605137F201758PleuralBiphasic605138F	21	F	2015	66	Pleural	Epithelioid	40	43
24M201567Pleural + peritonealEpithelioid356025M201778PeritonealBiphasic506226F201857PeritonealBiphasic255727F201314PeritonealEpithelioid121428F201667PeritonealEpithelioid155929F201873PleuralEpithelioid306530F201873PleuralBiphasic605531M201739TestisEpithelioid73932F201668PleuralSacomatoid575733F201668PleuralEpithelioid386444F201780PleuralEpithelioid155434F201663PleuralEpithelioid155435F201663PleuralEpithelioid155436F201758PleuralBiphasic205837F201758PleuralBiphasic607138F201471PleuralBiphasic607138F201470PleuralEpithelioid1439	22	F	2016	45	Pleural	Epithelioid	10	45
25M201778PeritonealBiphasic506226F201857PeritonealBiphasic255727F201314PeritonealEpithelioid121428F201667PeritonealEpithelioid155929F201873PleuralEpithelioid306530F201876PleuralBiphasic605531M201739TestisEpithelioid73932F201668PleuralSarcomatoid575733F201668PleuralEpithelioid386434F201780PleuralEpithelioid506035F201663PleuralEpithelioid506334F201758PleuralEpithelioid505435F201758PleuralBiphasic605136F201758PleuralBiphasic607137F201771PleuralBiphasic607138F201470PleuralEpithelioid4139	23	F	2018	45	Peritoneal	Epithelioid	39	45
26F201857PeritonealBiphasic255727F201314PeritonealEpithelioid121428F201667PeritonealEpithelioid155929F201873PleuralEpithelioid306530F201876PleuralBiphasic605531M201739TestisEpithelioid73932F201857PleuralSarcomatoid575733F201668PleuralEpithelioid386434F201780PleuralEpithelioid506035F201663PleuralEpithelioid506036F201758PleuralBiphasic605137F201758PleuralBiphasic605138F201771PleuralBiphasic6071	24	М	2015	67	Pleural + peritoneal	Epithelioid	35	60
27F201314PeritonealEpithelioid121428F201667PeritonealEpithelioid155929F201873PleuralEpithelioid306530F201876PleuralBiphasic605531M201739TestisEpithelioid73932F201857PleuralSarcomatoid575733F201768PleuralEpithelioid386434F201780PleuralEpithelioid506035F201663PleuralEpithelioid506036F201758PleuralEpithelioid155436F201771PleuralBiphasic607138F201470PleuralEpithelioid4139	25	М	2017	78	Peritoneal	Biphasic	50	62
28F201667PeritonealEpithelioid155929F201873PleuralEpithelioid306530F201876PleuralBiphasic605531M201739TestisEpithelioid73932F201857PleuralSarcomatoid575733F201668PleuralEpithelioid386434F201780PleuralEpithelioid506035F201663PleuralEpithelioid506436F201758PleuralEpithelioid505436F201758PleuralBiphasic607137F201471PleuralBiphasic613938F201470PleuralEpithelioid4139	26	F	2018	57	Peritoneal	Biphasic	25	57
29F201873PleuralEpithelioid306530F201876PleuralBiphasic605531M201739TestisEpithelioid73932F201857PleuralSarcomatoid575733F201668PleuralEpithelioid386434F201780PleuralEpithelioid506035F201663PleuralEpithelioid155436F201758PleuralBiphasic607137F201771PleuralBiphasic607138F201470PleuralEpithelioid6071	27	F	2013	14	Peritoneal	Epithelioid	12	14
30F201876PleuralBiphasic605531M201739TestisEpithelioid73932F201857PleuralSarcomatoid575733F201668PleuralEpithelioid386434F201780PleuralEpithelioid506035F201663PleuralEpithelioid155436F201758PleuralBiphasic205837F201771PleuralBiphasic607138F201470PleuralEpithelioid4139	28	F	2016	67	Peritoneal	Epithelioid	15	59
31M201739TestisEpithelioid73932F201857PleuralSarcomatoid575733F201668PleuralEpithelioid386434F201780PleuralEpithelioid506035F201663PleuralEpithelioid155436F201758PleuralBiphasic205837F201771PleuralBiphasic607138F201470PleuralEpithelioid4139	29	F	2018	73	Pleural	Epithelioid	30	65
32F201857PleuralSarcomatoid575733F201668PleuralEpithelioid386434F201780PleuralEpithelioid506035F201663PleuralEpithelioid155436F201758PleuralBiphasic205837F201771PleuralBiphasic607138F201470PleuralEpithelioid4139	30	F	2018	76	Pleural	Biphasic	60	55
33F201668PleuralEpithelioid386434F201780PleuralEpithelioid506035F201663PleuralEpithelioid155436F201758PleuralBiphasic205837F201771PleuralBiphasic607138F201470PleuralEpithelioid4139	31	М	2017	39	Testis	Epithelioid	7	39
34F201780PleuralEpithelioid506035F201663PleuralEpithelioid155436F201758PleuralBiphasic205837F201771PleuralBiphasic607138F201470PleuralEpithelioid4139	32	F	2018	57	Pleural	Sarcomatoid	57	57
35F201663PleuralEpithelioid155436F201758PleuralBiphasic205837F201771PleuralBiphasic607138F201470PleuralEpithelioid4139	33	F	2016	68	Pleural	Epithelioid	38	64
36F201758PleuralBiphasic205837F201771PleuralBiphasic607138F201470PleuralEpithelioid4139	34	F	2017	80	Pleural	Epithelioid	50	60
37         F         2017         71         Pleural         Biphasic         60         71           38         F         2014         70         Pleural         Epithelioid         41         39	35	F	2016	63	Pleural	Epithelioid	15	54
38 F 2014 70 Pleural Epithelioid 41 39	36	F	2017	58	Pleural	Biphasic	20	58
	37	F	2017	71	Pleural	Biphasic	60	71
39         F         2016         26         Peritoneal         Epithelioid         20         26	38	F	2014	70	Pleural	Epithelioid	41	39
	39	F	2016	26	Peritoneal	Epithelioid	20	26

## TABLE 1 (Continued)

Case	Sex	Year of diagnosis	Age at diagnosis	Mesothelioma site	Histology	Estimated years of use	Estimated years of latency
40	F	2016	35	Pleural	Epithelioid	35	35
41	F	2017	72	Pleural	Sarcomatoid	23	60
42	F	2016	68	Peritoneal	Epithelioid	65	68
43	F	2018	77	Pleural	Biphasic	30	55
44	М	2015	58	Plural	Biphasic	6	49
45	F	2017	72	Peritoneal	Biphasic	30	42
46	F	2017	59	Pleural + peritoneal	Epithelioid	15	44
47	F	2016	80	Pleural	Biphasic	16	52
48	М	2019	71	Pleural	Epithelioid	40	57
49	F	2017	72	Pleural	Biphasic	58	58
50	F	2017	43	Peritoneal	Epithelioid	43	43
51	F	2017	75	Peritoneal	Sarcomatoid	55	59
52	F	2015	30	Pleural	Epithelioid	20	20
53	F	2017	79	Pleural	Biphasic	65	61
54	F	2017	66	Peritoneal	Epithelioid	20	60
55	F	2015	64	Peritoneal	Epithelioid	40	40
56	F	2017	24	Pleural	Epithelioid	12	24
57	М	2017	72	Pleural	Epithelioid	30	56
58	М	2017	74	Peritoneal	Epithelioid	30	52
59	М	2015	30	Pleural	Epithelioid	20	30
60	F	2016	81	Pleural	Sarcomatoid	52	52
61	F	2017	58	Pleural	Epithelioid	58	58
62	F	2016	75	Pleural	Epithelioid	8	47
63	F	2011	88	Pleural	Epithelioid	21	71
64	F	2016	73	Peritoneal	Biphasic	41	60
65 <sup>a</sup>	М	2017	64	Pleural	Epithelioid	18	40
66 <sup>a</sup>	F	2014	69	Pleural	Epithelioid	16	60
67 <sup>a</sup>	F	2014	44	Peritoneal	Epithelioid	30	39
68 <sup>a</sup>	F	2016	68	Pleural	Epithelioid	53	52
69 <sup>a</sup>	F	2016	72	Pleural	Epithelioid	40	51
70 <sup>a</sup>	F	2016	67	Pleural	Epithelioid	37	53
71 <sup>a</sup>	F	2017	58	Pleural	Epithelioid	41	46
72 <sup>a</sup>	М	2016	44	Pleural	Epithelioid	43	44
73 <sup>a</sup>	F	2017	51	Pleural	Epithelioid	28	49
74 <sup>a</sup>	F	2015	47	Pleural	Epithelioid	15	40
75 <sup>a</sup>	F	2014	62	Pleural	Biphasic	14	53

<sup>a</sup>Tissue analysis performed.

The present study has several limitations. It is both retrospective and uncontrolled, and the cases were submitted in medico-legal consultation, all of which potentially introduce bias. However, detailed deposition testimonies provide a level of detail concerning product exposure—including dates of exposure, duration, and frequency—that is rarely obtained in routine medical exposure histories, and which allowed for corroborating witness testimony in some cases. The strengths of the current series include its size, as malignant mesothelioma is a rare disease

ee J	Macothaliama cita	A chector from	Tiscuse avaminad	Concentration (fibers per gram of wet tissue) Lung, lymph node, omentum,	Limit of detection (fibers per gram of wet tissue) Lung, lymph node, omentum,	Tissue digest weight (g) Lung, lymph node, omentum,
Case						
65	Pleural	Anthophyllite, tremolite	Lung, lymph node	8625	4313	0.08, 0.34
99	Pleural	Anthophyllite	Lung, lymph node	15 333, 23 000	7667, 1150	0.06, 0.06
67	Peritoneal	Anthophyllite, tremolite	Omentum, lymph node	1917, 1725	639, 1725	0.54, 0.20
68	Pleural	Anthophyllite, tremolite	Lymph node	3044	1015	0.82, 0.34
70	Pleural	Anthophyllite, amosite, chrysotile	Lymph node	17 250	3450	1.06
71	Pleural	Anthophyllite, tremolite	Lung, lymph node	4313, 857, 3451	2156, 857, 575	0.16
72	Pleural	Anthophyllite, tremolite	Lymph node	17 250	3450	0.02
74	Pleural	Anthophyllite, tremolite	Lung	2300	460	2
75	Pleural	Anthophyllite	Lung, ovary	3450, 2070	1150, 2070	0.6, 0.2
Note: All	eve even umore sess	Note: All csees shown were evamined by analytical transmission electron microscomy and structures analyzed by microwohe analysis	ron microscopy and structu	Ires analyzed by microprobe analysis		

Note: All cases shown were examined by analytical transmission electron microscopy and structures analyzed by microprobe analysis.

AMERICAN JOURNAL OF NDUSTRIAL MEDICINE

488

(1-2 cases per 100 000), and its novelty, as exposures to cosmetic talc are rarely considered by most medical practitioners when they are eliciting an exposure history to asbestos.

The findings of the present and other recent studies suggest that cosmetic talc may be a cause of malignant mesothelioma. Large-scale controlled studies will be required to assess the prospective risk of developing mesothelioma following repeated exposures to talc. Although cosmetic talcs are not currently regulated by the Food and Drug Administration, the poor prognosis of malignant mesothelioma may warrant regulation or the withdrawal of cosmetic talcs from the market, as nontoxic alternatives such as corn starch are presently available.

## CONFLICTS OF INTEREST

Drs Emory, Maddox, and Kradin have testified in asbestos litigation, primarily for plaintiffs.

### DISCLOSURE BY AJIM EDITOR OF RECORD

John D. Meyer declares that he has no conflict of interest in the review and publication decision regarding this article.

## AUTHOR CONTRIBUTIONS

JCM and RLK developed the concept and the design of the work. JCM initiated the acquisition and developed the initial data analysis. TSE reviewed the materials, performed the statistical analysis, and was the primary author of the manuscript. RLK revised and gave the final approval of the version to be published.

## ETHICS APPROVAL AND INFORMED CONSENT

As these cases were selected from medical-legal consultation practice and no identifying information was included, there was no formal institutional consent nor informed consent required.

## ORCID

 Theresa S. Emory (b) http://orcid.org/0000-0002-8075-4480

 John C. Maddox (b) http://orcid.org/0000-0003-1417-0337

 Richard L. Kradin (b) http://orcid.org/0000-0002-3953-8671

#### REFERENCES

- Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Occup Environ Med. 1960;17:260-271.
- Lacourt A, Gramond C, Rolland P, et al. Occupational and nonoccupational attributable risk of asbestos exposure for malignant pleural mesothelioma. *Thorax.* 2014;69:532-539.
- Rödelsperger K, Jöckel KH, Pohlabeln H, Romer W, Woitowitz HJ. Asbestos and man-made vitreous fibers as risk factors for diffuse malignant mesothelioma: results from a German hospital-based casecontrol study. Am J Ind Med. 2001;39:262-275.
- Jiang Z, Chen T, Chen J, et al. Hand spinning chrysotile exposure and risk of malignant mesothelioma: a case control study in Southeastern China. *Int J Cancer.* 2018;142:514-523.

- 5. Rohl AN, Langer AM. Identification and quantitation of asbestos in talc. *Environ Health Perspect*. 1974;9:95-109.
- Rohl AN, Langer AM, Selikoff IJ, et al. Consumer talcums and powders: mineral and chemical characterization. J Toxicol Environ Health. 1976;2:255-284.
- Snider D, Pfeiffer D, Mancusco J. Asbestos form impurities in commercial talcum powders. Compass Sigma Gamma Epsilon. 1972;49:65-67.
- Gordon RE, Fitzgerald S, Millette J. Asbestos in commercial cosmetic talcum powder as a cause of mesothelioma in women. Int J Occup Environ Health. 2014;20(4):318-332.
- Moline J, Bevilacqua K, Alexandri M, Gordon RE. Mesothelioma associated with the use of cosmetic talc. J Occup Environ Med. 2020;62(1):11-17.
- Steffen JE, Tran T, Yimam M, et al. Serous ovarian cancer caused by exposure to asbestos and fibrous talc in cosmetic talc powders—A case series. J Occup Environ Med. 2020;62:e65-e73. https://doi.org/10. 1097/JOM.00000000001800
- Paoletti L, Caiazza S, Donelli G, Pocchiari F. Evaluation by electron microscopy techniques of asbestos contamination in industrial, cosmetic, and pharmaceutical talcs. *Regulatory Toxicol Pharmacol.* 1984;4:222-235.
- 12. Roggli V, Vollmer R, Kelly J, Sporn T. Tremolite and mesothelioma. *Ann Occup Hyg.* 2002;46(5):447-453.
- Millman N. Pneumoconiosis due to talc in the cosmetic industry. Occup Med. 1947;3:257-260.
- Kleinfeld M, Messite J, Langer AM. A study of workers exposed to asbestiform minerals in commercial talc manufacture. *Environ Res.* 1973;6:132-143.
- Johns-Manville Research and Engineering Center. Body Talcum Powders-Petrographic Examination, requested by J. P. Leineweber. 31 October 1968. https://cdn.toxicdocs.org/gb/gbq4wMVNy39gQpYQo Rr0EpBE3/gbq4wMVNy39gQpYQoRr0EpBE3.pdf. Accessed 29 February 2020.
- Lewin S, New York University, to Alfred Weissler, FDA, August 3, 1972, https://cdn.toxicdocs.org/85/85JyymOw7EB568x1mExoqRQVe/ 85JyymOw7EB568x1mExoqRQVe.pdf. Accessed 29 February 2020.
- 17. Churg AM, Warnock ML. Asbestos and other ferruginous bodies their formation and clinical significance. *Am J Pathol.* 1981;102: 447-457.
- Roggli VL, McGavran MH, Subach J, Sybers HD, Greenberg SD. Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma. *Cancer.* 1982; 50:2423-2432.
- American Cancer Society. Key Statistics About Malignant Mesothelioma; 2018. https://www.cancer.org/cancer/malignant-mesothelioma/about/ key-statistics.html. Accessed 15 February 2020.
- Henley SJ, Larson TC, Wu M, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008. Int J Occup Environ Health. 2013;19(1):1-10. https://doi.org/10.1179/ 2049396712Y.000000016

How to cite this article: Emory TS, Maddox JC, Kradin RL. Malignant mesothelioma following repeated exposures to cosmetic talc: A case series of 75 patients. *Am J Ind Med*. 2020;63:484–489. https://doi.org/10.1002/ajim.23106

WILEY